Results 251 to 260 of about 234,058 (316)

Editorial: Advances in therapeutic cancer vaccines-mechanisms and development. [PDF]

Front Immunol
George MM, Brennick CA, Moon JJ, Lihm J, Choi H.   +4 more
europepmc   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Non-small cell lung cancer research: advances and persistent challenges. [PDF]

Front Oncol
Zhou L, Jiang J.
europepmc   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial. [PDF]

Future Oncol
Hao S, Wang X, Ding H, Chen Y, Liu Q, Zhang J, Fan X, Wu Z, Lin Y, Xu X, Mao G, Ai D, Deng J, Zhu H, Ye J, Mo M, Hu Z, Wang H, Cheng W, Feng W, Ling Y, Xu Y, Du S, Wang J, Zhao K.   +24 more
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227. [PDF]

J Thorac Dis
Kobayashi T, Nakamura S, Hakozaki T.
europepmc   +1 more source

Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer. [PDF]

Int J Nanomedicine
Sun S, Huang H, Hong H, Lu W, Qiu L, Liu S, Huang S, Ye K, Sun J, Lai G, Liu J.   +10 more
europepmc   +1 more source

The double face of IL-1β in lung cancer. [PDF]

Oncoimmunology
Rébé C, Perrichet A, Ghiringhelli F.
europepmc   +1 more source